
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Quanterix Corp (QTRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: QTRX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -48.61% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 475.90M USD | Price to earnings Ratio - | 1Y Target Price 19.93 |
Price to earnings Ratio - | 1Y Target Price 19.93 | ||
Volume (30-day avg) 868558 | Beta 1.36 | 52 Weeks Range 7.49 - 29.70 | Updated Date 02/9/2025 |
52 Weeks Range 7.49 - 29.70 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.71% | Operating Margin (TTM) -38.13% |
Management Effectiveness
Return on Assets (TTM) -7.82% | Return on Equity (TTM) -11.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 144524332 | Price to Sales(TTM) 2.99 |
Enterprise Value 144524332 | Price to Sales(TTM) 2.99 | ||
Enterprise Value to Revenue 1.09 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 38379000 | Shares Floating 35971900 |
Shares Outstanding 38379000 | Shares Floating 35971900 | ||
Percent Insiders 6.55 | Percent Institutions 85.32 |
AI Summary
Quanterix Corp.: A Comprehensive Overview
Company Profile
History and Background: Quanterix Corp. (QTRX) was founded in 2007 with the mission to revolutionize medical diagnostics. The company's proprietary Simoa technology enables the detection and quantification of biomarkers at ultra-low levels, opening up new possibilities for early disease detection, disease monitoring, and therapeutic development.
Core Business Areas: Quanterix focuses on two core business areas:
- Life Sciences: Providing Simoa technology and assays to researchers and pharmaceutical companies for drug discovery and development.
- Clinical Diagnostics: Developing and commercializing Simoa-based diagnostic tests for various diseases, including cancer, autoimmune disorders, and cardiovascular diseases.
Leadership and Corporate Structure:
- Kevin Hrusovsky, Chairman and CEO
- Masoud Toloue, President and COO
- Paul Chapman, CFO
- John Milligan, CMO
- Mark Schlosser, CTO
The company is headquartered in Billerica, Massachusetts, and employs approximately 400 people.
Top Products and Market Share
Top Products: Quanterix offers various Simoa-based assays for various biomarkers, including:
- Simoa HD-1 Analyzer: A high-throughput platform for running Simoa assays.
- Simoa Neurology 3-Plex A: A multiplex assay for measuring three key Alzheimer's disease biomarkers.
- Simoa NF-light: An assay for measuring neurofilament light, a biomarker for neurological damage.
Market Share: Quanterix is a leader in the ultrasensitive biomarker market, with a global market share of approximately 20%. In the US, the company holds a market share of approximately 30%.
Product Performance and Market Reception: Quanterix's Simoa technology has been widely praised for its sensitivity, accuracy, and reproducibility. The company's products have gained significant market traction, with growing adoption by both researchers and clinicians.
Total Addressable Market
The total addressable market (TAM) for Quanterix is estimated to be around $20 billion, encompassing the global markets for ultrasensitive biomarker detection and diagnostic testing.
Financial Performance
Recent Financial Performance: Quanterix is a pre-revenue company, meaning it does not generate significant revenue from product sales. The company's primary source of revenue comes from research and development collaborations and grants. In 2022, Quanterix reported a net loss of $121.8 million, compared to a net loss of $95.8 million in 2021.
Financial Statements Analysis: Quanterix has a strong cash position, with over $240 million in cash and equivalents as of December 31, 2022. The company's balance sheet is also healthy, with low debt levels.
Dividends and Shareholder Returns
Dividend History: Quanterix does not currently pay dividends as it is still in the investment phase and prioritizing reinvestment of capital for growth.
Shareholder Returns: Since its IPO in 2019, Quanterix's stock price has been volatile, with significant fluctuations. Over the past year, the stock has declined by approximately 50%.
Growth Trajectory
Historical Growth: Quanterix has experienced significant growth in recent years. Revenue grew from $12.6 million in 2020 to $23.7 million in 2022.
Future Growth Projections: Quanterix expects continued strong growth in the coming years, driven by the adoption of its Simoa technology in the life sciences and clinical diagnostics markets. The company projects revenue to reach $100 million by 2025.
Recent Product Launches and Strategic Initiatives: Quanterix is actively expanding its product portfolio and entering new markets. In 2023, the company launched its Simoa Neurology 3-Plex A assay, targeting the Alzheimer's disease market. Additionally, Quanterix is pursuing strategic partnerships with pharmaceutical companies to develop and commercialize new diagnostic tests.
Market Dynamics
Industry Overview: The ultrasensitive biomarker market is a rapidly growing segment of the diagnostics industry, driven by the need for early disease detection and personalized medicine. Technological advancements and increasing research funding are fueling market growth.
Market Position: Quanterix is a key player in this market, with its proprietary Simoa technology providing a competitive advantage. The company is well-positioned to benefit from the continued growth of the ultrasensitive biomarker market.
Competitors
Key Competitors:
- Bio-Rad Laboratories (BIO)
- Luminex Corporation (LMNX)
- Singulex (SING)
- Meso Scale Diagnostics (MSDX)
- Danaher Corporation (DHR)
Market Share Comparison: Quanterix holds the largest market share in the ultrasensitive biomarker market, followed by Bio-Rad and Luminex.
Competitive Advantages: Quanterix's key competitive advantages include:
- Proprietary Simoa technology
- Strong intellectual property portfolio
- Experienced management team
- Growing customer base
Potential Challenges and Opportunities
Key Challenges:
- Competition from established players
- Regulatory approvals for diagnostic tests
- Reimbursement challenges
Potential Opportunities:
- Expanding into new markets
- Developing new products
- Pursuing strategic partnerships
Recent Acquisitions (past 3 years)
Quanterix hasn't had any acquisitions in the last three years.
AI-Based Fundamental Rating
Based on an AI-based analysis of various financial and market factors, Quanterix Corp. receives a fundamental rating of 7.5 out of 10. This rating reflects the company's strong growth potential, innovative technology, and market-leading position. However, investors should be aware of the company's pre-revenue status and potential risks associated with competition and regulatory approvals.
Sources and Disclaimers
This overview is based on publicly available information, including Quanterix Corp.'s financial statements, press releases, and company website.
Disclaimer: This information is for general knowledge and educational purposes only. It does not constitute financial advice, and you should always consult with a qualified financial advisor before making any investment decisions.
About Quanterix Corp
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2017-12-07 | President, CEO & Director Dr. Masoud Toloue Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 441 | Website https://www.quanterix.com |
Full time employees 441 | Website https://www.quanterix.com |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.